Grifols reorganizes its biopharma business and separates the US from the rest of the world

BarcelonaGrifols reorganizes the structure of its biopharmaceutical business, which contributes the most to the company's revenue. As announced in a statement, it will create "differentiated organizations" for biopharma for the United States, the Catalan company's main market, and for the rest of the world. According to the pharmaceutical company, this move serves to "further strengthen the operational and financial independence of the subsidiaries." In this way, plasma collected in the United States will be used to cover the country's market, while that extracted in the rest of the world will go to the European market and other environments where the company operates.

Grifols' biopharmaceutical business in the United States is the largest in the sector, with nearly 300 plasma donation centers and two major industrial plants. It is worth noting that it has recently sought to diversify plasma procurement and the processing of plasma-derived medicines. It has done so, in large part, through the expansion of its joint initiative with the Egyptian government, Grifols Egypt for Plasma Derivatives, which will mobilize a total investment of 460 million euros.

Within the reorganization, Grifols has appointed Felipe Palacios as the new senior vice president of biopharma for the United States. Palacios, with more than 25 years of experience in the industry, will lead commercial operations in the country. The head of the biopharma business in the rest of the world will be senior vice president of the segment, Thierry Heinrich. According to the non-executive chairwoman of the multinational, Anne-Cathrine Berner, the change serves to "build a more efficient, resilient, and profitable operating model." "The autonomy of the platforms will strengthen execution and accelerate decision-making," she added.

On the stock market "to recognize the value"

The separation of biopharma in the US than the rest of the world is taking place at a moment of special strategic relevance, in which the company continues to study the stock market flotation of part of its North American business. The pharmaceutical company, it should be recalled, opened the door to the sea by launching a public sale offer for a minority stake in the North American segment of biopharma, a business that "operates in the world's largest plasma market and is fully integrated".

As the president indicated in his intervention at the general shareholders' meeting, held in mid-June, the stock market operation would serve to "highlight the extraordinary value" of the company's infrastructure in the United States. The global biopharmaceutical vertical, it should be remembered, contributed 6,485 million euros to the Catalan company's turnover in 2025, 86% of the group's total revenue.